Two-Drug HER2 attack vs one: which First-Line strategy helps advanced breast cancer patients live longer?
Disease control
Completed
Researchers are comparing two first-line treatment strategies for women with advanced HER2-positive breast cancer: pertuzumab plus trastuzumab and docetaxel, versus trastuzumab and docetaxel alone. The study uses real-world electronic health records from about 2,250 patients trea…
Sponsor: Xin Li • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC